Two pills beat chemotherapy for EGFR lung cancer that escapes through MET
For one type of EGFR lung cancer, a two-pill combination kept the cancer from growing longer and shrank more tumors than chemotherapy. Here is what to ask your oncologist.
Cancer
Screening, treatment and life after cancer.
Colorectal cancer in the liver: a faster surgery lets more people have tumors removed
A Cochrane review found that ALPPS, a staged liver surgery, lets many more people with colorectal cancer in the liver have their tumors removed, with survival similar to the standard approach.
New lung cancer treatment kept a hard-to-treat tumor type in check far longer
In a large trial, people with advanced lung cancer that is PD-L1-negative went a median 15.0 months without their cancer growing on a new combination. Standard care gave 5.7 months.
Melanoma immunotherapy pair still working at five years, and you can check your skin today
People with advanced melanoma who got relatlimab plus nivolumab still lived longer than those on nivolumab alone after five years. A two-minute skin check tonight is a good habit.
Bladder cancer: a protein blocker helped immunotherapy clear more tumors before surgery
In a new trial, adding visugromab to immunotherapy before surgery left no cancer behind in one in three bladder cancer patients, compared with about one in twelve on immunotherapy alone.
New lung cancer drug kept tumors in check about twice as long as chemo
In a large phase 3 trial, people with EGFR lung cancer who had run out of pill options went about twice as long without their cancer growing on iza-bren as on chemo.…
New first treatment for HER2-positive breast cancer holds back women’s cancers longer
In a large phase 3 trial, a new antibody paired with chemo kept far more women with advanced HER2-positive breast cancer from progressing at two years. Here is what it means and…
Lymphoma of the skin: how 6 newer drugs compare, with response rates from 34% to 69%
A review of 41 studies compared newer targeted and immune drugs for cutaneous T-cell lymphoma. Response rates differ by drug and by subtype, which gives you better questions to ask the specialist.
Early trial: a new immunotherapy drug shrank some tumors that usually resist it
A new T cell drug, invikafusp alfa, shrank tumors in some people whose cancers had ignored other immunotherapy. It is early, but it shows a new way to wake up the immune…
Women’s cancers: new guideline calls for genetic testing in all advanced ovarian cancer
A new ASCO guideline says everyone newly diagnosed with advanced ovarian cancer should get genetic testing. It also points PARP inhibitor pills to the stage where they help most.
Mailed home kits raised colorectal cancer screening at 2 years, then the gap narrowed
In community health centers, mailing a home stool test kit got more people screened for colorectal cancer by year 2. By year 3 the gap had narrowed. Your own screening date is…